| First Author | Kett LR | Year | 2016 |
| Journal | Mov Disord | Volume | 31 |
| Issue | 10 | Pages | 1433-1443 |
| PubMed ID | 27619535 | Mgi Jnum | J:234907 |
| Mgi Id | MGI:5792390 | Doi | 10.1002/mds.26797 |
| Citation | Kett LR, et al. (2016) Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges. Mov Disord 31(10):1433-1443 |
| abstractText | Increasingly, genetic, cell biological, and in vivo work emphasizes the role of the endolysosomal system dysfunction in Parkinson's disease pathogenesis. Yet many questions remain about the mechanisms by which primary endolysosomal dysfunction causes PD as well as how the endolysosomal system interacts with alpha-synuclein-mediated neurotoxicity. We recently described a new mouse model of parkinsonism in which loss of the endolysosomal protein Atp13a2 causes behavioral, neuropathological, and biochemical changes similar to those present in human subjects with ATP13A2 mutations. In this Scientific Perspectives, we revisit the evidence implicating the endolysosomal system in PD, current hypotheses of disease pathogenesis, and how recent studies refine these hypotheses and raise new questions for future research. (c) 2016 International Parkinson and Movement Disorder Society. |
